Boston Scientific CORP Form 4 insider transactions

Vance R Brown, SVP, GC and Corp. Secretary of Boston Scientific, reports multiple transactions involving common stock and restricted stock units, including acquisitions and disposals, from February 13, 2025, to February 17, 2025.

Daniel J. Brennan, EVP and CFO of Boston Scientific, reports the acquisition and disposal of company stock and derivative securities.

Emily Woodworth, SVP, Global Controller and CAO of Boston Scientific, reports the vesting of restricted stock units and subsequent disposal of shares to cover tax obligations.

John Bradley Sorenson, EVP of Global Operations at Boston Scientific, reported the vesting of restricted stock units and subsequent tax withholding.

Miriam O'Sullivan, SVP, Chief HR Officer at Boston Scientific, reports transactions involving common stock and restricted stock units.

Michael Mahoney, Chairman, President & CEO of Boston Scientific, reports acquisition and disposal of common stock and restricted stock units.

EVP Jeffrey B. Mirviss of Boston Scientific reports the vesting of restricted stock units and associated tax withholding.

Executive Vice President of Boston Scientific, Joseph Michael Fitzgerald, reports the acquisition and disposal of company stock and restricted stock units.

Arthur C. Butcher, EVP & Group President at Boston Scientific, executed stock options and disposed of shares on February 12, 2025.

Vance R. Brown, SVP, GC and Corp. Secretary of Boston Scientific, reports the acquisition and disposal of common stock and restricted stock units.

Daniel J. Brennan, EVP and CFO of Boston Scientific, reports the vesting of restricted stock units and subsequent tax withholding.

Executive Vice President of Global Operations at Boston Scientific, John Bradley Sorenson, reports acquisition and disposal of company stock, including transactions related to performance share units and sales under a pre-established trading plan.

Jeffrey B. Mirviss, EVP & President of Peripheral Interventions at Boston Scientific, sold 13,022 shares of common stock after performance share units vested.

Michael Mahoney, Chairman, President & CEO of Boston Scientific, reports acquisition and disposal of common stock on February 11, 2025, according to a Form 4 filing.

Executive Vice President of Boston Scientific, Joseph Michael Fitzgerald, reports a series of transactions involving company stock, including purchases, sales, and the vesting of performance share units.

Executive Arthur C. Butcher reports acquisition and disposal of Boston Scientific shares, including performance share units and transactions related to a 401(k) plan.

Vance R. Brown, SVP, GC and Corp. Secretary of Boston Scientific, reports the vesting of performance share units and a transaction for tax withholding.

Daniel J. Brennan, EVP and CFO of Boston Scientific, exercised stock options and sold shares of common stock on February 11th and 12th, 2025, according to a Form 4 filing with the SEC.

Director Edward J. Ludwig sold 12,000 shares of Boston Scientific (BSX) common stock at an average price of $105.4846 on February 11, 2025, while also receiving 3,000 shares as a gift.

John Bradley Sorenson, EVP of Global Operations at Boston Scientific, reports the sale of 6,528 shares of common stock at a price of $104.97 per share.

EVP Arthur C. Butcher of Boston Scientific Corp. exercised stock options and sold shares of common stock on February 3, 2025, under a pre-established Rule 10b5-1 trading plan.

EVP of Global Operations at Boston Scientific, John Bradley Sorenson, reports transactions involving common stock and performance share units.

Michael Mahoney, Chairman, President & CEO of Boston Scientific, reports the vesting and conversion of performance share units and associated stock transactions.

Jeffrey B. Mirviss, EVP & President of Peripheral Interventions at Boston Scientific, reports the vesting of performance share units and subsequent sale of shares.

Joseph Michael Fitzgerald, EVP & Group President of Cardiology at Boston Scientific, exercised performance share units and disposed of shares on January 1, 2025.

Arthur Butcher, EVP & Group President at Boston Scientific, reports the vesting and conversion of performance share units and a disposition of shares to cover tax obligations.

Vance R. Brown, a Boston Scientific executive, reports the vesting and subsequent disposition of performance share units, along with associated tax withholding.

Daniel J. Brennan, EVP and CFO of Boston Scientific, reports the vesting of performance share units, subsequent sale of shares, and resulting changes in beneficial ownership of company stock.

Boston Scientific's Executive Vice President of Human Resources, Wendy Carruthers, exercised stock options and sold shares of common stock under a pre-established 10b5-1 trading plan.

Emily Woodworth, a Senior Vice President at Boston Scientific, sold 1,336 shares of common stock at an average price of $90.6476 on November 27, 2024.